Cytokinetics | CYTK - Current Assets


Cytokinetics reported $839.46M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Arca Biopharma USD 395.25M 51.39M Mar/2026
Bayer EUR 35.3B 2.39B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
Brainstorm Cell Therapeutics USD 184K 123K Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Capricor Therapeutics USD 283.09M 39.85M Mar/2026
Cytokinetics USD 839.46M 77.51M Mar/2026
Eisai JPY 761.64B 79.24B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Exelixis USD 1.21B 234.65M Mar/2026
Geron USD 498.53M 21.74M Mar/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.16B 789M Mar/2026